Dina Morshedi
National Institute of Genetic Engineering and Biotechnology, Iran.
Title: Using Nanocarriers against Synucleinopathies
Biography
Biography: Dina Morshedi
Abstract
α-Synuclein (α-Syn) is a protein presence in the brains of a range of neurodegenerative disorders’ patients as plaque-like compact structures in the form of amyloid fibrils. There is a strong relationship between α-Syn amyloid fibrillation and the pathology of the neurodegenerative disorders such as Parkinson’s disease. There is a serious effort to apply the compounds, known as small molecules, with inhibitory effects on the different steps of α-SN fibrillation and also its related neurotoxicity. However, the small molecules can possess some problems like high hydrophobicity/ low solubility in physiological fluids, instability, and difficulty in passing across blood brain barrier (BBB). In this respect, employing of nanocarriers has been pointed because of a lot of advantages i.e. biocompatibility, easy surface modification, low immunogenicity, protecting cargo against enzymatic degradation. In this regard we used three different nanocarriers including serum albumin nanoparticles (SA- NPs)([1], mesoporous silica nanoparticles (MS-NPs) [2] and neutral charged nanoliposomes(NC-NLPs). We found that each kind of nanocarrier possess specific characters when applying for loading drugs or treating α-Syn or neuronal cells. SA- NPs with a moderate drug loading efficiency (DLE) for polyphenols, showed some inducing effect on α-Syn fibrillation when treating with bare SA- NPs. Although MS-NPs with similar DLE did not show inducing effect on α-Syn fibrillation, they had a small neurotoxicity effect. On the other hand, NC-NLPs had high DLE for polyphenols and also they did not indicate any considerable induction on the α-Syn fibrillation or any neurotoxicity effects. It seems that NC-NLPs have more potential for using regarding synucleinopathies treating than the two other NPs.